trending Market Intelligence /marketintelligence/en/news-insights/trending/Tj6tkcYe1paHLH-7eehSzA2 content esgSubNav
In This List

AstraZeneca sells rights to cancer drug for $250M

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


AstraZeneca sells rights to cancer drug for $250M

TerSera Therapeutics LLC acquired the U.S. and Canadian rights to AstraZeneca PLC's cancer drug Zoladex for an up-front payment of $250 million and up to a further $70 million in milestone-related payments and royalties on the drug's sale.

The sale was first announced in February.

Zoladex is an injectable luteinizing hormone-releasing medicine for treating prostate cancer, breast cancer and certain benign gynecological disorders, and was first approved in the U.S. and Canada in 1989.